Bollard Group’s Intellia Therapeutics NTLA Stock Holding History

Bollard Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-734	Closed	-$53K	–	366
2022 Q1	$53K	Hold	734	–	–	﹤0.01%	335
2021 Q4	$87K	Hold	734	–	–	﹤0.01%	306
2021 Q3	$98K	Hold	734	–	–	﹤0.01%	285
2021 Q2	$119K	Hold	734	–	–	﹤0.01%	263
2021 Q1	$59K	Hold	734	–	–	﹤0.01%	333
2020 Q4	$40K	Hold	734	–	–	﹤0.01%	354
2020 Q3	$15K	Hold	734	–	–	﹤0.01%	396
2020 Q2	$15K	Buy	+734	New	+$12.5K	﹤0.01%	419

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bollard Group's NTLA Position: Q2 2022 in Review

Bollard Group sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 734 shares — an estimated $53K sold.

Bollard Group first reported a position in NTLA in Q2 2020 and held it in 8 quarters. The position peaked at $119K in Q2 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Bollard Group reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 734 Intellia Therapeutics shares in Q2 2022, an estimated $53K.
Bollard Group first reported a position in Intellia Therapeutics in Q2 2020 and held it in 8 quarters.
Bollard Group's Intellia Therapeutics position peaked at $119K in Q2 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.